Subscribe
Models
HUGO Series 🌟
Cell Line Models
Services
Preclinical Efficacy
Resources
About Us
H11-hB2M&HLA-A11 Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
H11-hB2M&HLA-A11 Mouse
Product Name
H11-hB2M&HLA-A11 Mouse
Product ID
I001139
Strain Name
C57BL/6NCya-Igs2em1(B2M/HLA-A11/H2-D1)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “H11-hB2M&HLA-A11 Mouse (Catalog I001139) were purchased from Cyagen.”
Other Target Humanized Mouse Models
Safe Harbor Knock-in
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Other Target Humanized Mouse Models
Safe Harbor Knock-in
Basic Information
Validation Data
Related Resource
Basic Information
Gene Name
B2M & HLA-A
Gene Alias
IMD43, HLAA
NCBI ID
Chromosome
Chr 15 (Human), Chr 6 (Human)
MGI ID
--
Datasheet
Strain Description
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3].
HLA-A11 is one of the most common HLA class I alleles and is associated with infectious diseases (such as familial otosclerosis, pulmonary tuberculosis, and leprosy), tumors, and autoimmune diseases. The H11-hB2M&HLA-A11 mouse model is constructed by integrating the chimeric H2-K1 HLA-A11 gene into the H11 safe harbor locus of mice using gene editing technology. This mouse model can be used to identify viral peptides that express HLA-A11 binding sequences.
Reference
La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 2002 Nov 15;100(10):3681-9.
Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLA-A2402/K(b) transgenic mice. Int J Cancer. 2002 Aug 10;100(5):565-70.
Boucherma R, Kridane-Miledi H, Bouziat R, Rasmussen M, Gatard T, Langa-Vives F, Lemercier B, Lim A, Bérard M, Benmohamed L, Buus S, Rooke R, Lemonnier FA. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J Immunol. 2013 Jul 15;191(2):583-93.
Strain Strategy
The Mouse K2-K1 promoter- Kozak-HLA-A2.1 leader sequence-Human Mature B2M CDS-3xGGGGSChimeric HLA-A11 (HLA-A11 alpha1 and alpha2 binding domains-H2-D1 alpha3, cytoplasmic and transmembrane domains)-H2-D1 3’sequence was integrated into the mouse H11 safe harbor site.

Figure 1. Gene editing strategy of H11-hB2M&HLA-A11 mice.
Application Area
Research on human viral infectious diseases;
Development and testing of novel viral vaccines;
Safety and immunogenicity testing of drugs and vaccines;
Research on oncology and autoimmune diseases;
Study of the interactions between human immune cells and pathogens;
Research on homologous tumor transplantation (Syngeneic).
Validation Data
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

